{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:30:16Z","timestamp":1782307816612,"version":"3.54.5"},"reference-count":70,"publisher":"Informa UK Limited","issue":"21","funder":[{"name":"NIH and Novartis Pharmaceuticals"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.2217\/fon-2017-0160","type":"journal-article","created":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T08:53:31Z","timestamp":1497430411000},"page":"1853-1871","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Midostaurin for the treatment of acute myeloid leukemia"],"prefix":"10.1080","volume":"13","author":[{"given":"Mrinal M","family":"Patnaik","sequence":"first","affiliation":[{"name":"Department of Hematology,Mayo Clinic,\rRochester,\rMN 55905,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,6,14]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2016.09.001"},{"key":"e_1_3_2_4_1","first-page":"109","volume-title":"WHO Classification of Tumours (4th Edition).","author":"Swerdlow SH","year":"2008","unstructured":"Swerdlow SH , CampoE, HarrisNLet al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. In: WHO Classification of Tumours (4th Edition). (Volume 2). IARC, 109\u2013138 (2008)."},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0492"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25908"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1752"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209999"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2014.960843"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1280-6"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-578070"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015826"},{"issue":"1","key":"e_1_3_2_15_1","first-page":"19","article-title":"Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia","volume":"88","author":"Moreno I","year":"2003","unstructured":"Moreno I , MartinG, BoluferPet al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica88(1), 19\u201324 (2003).","journal-title":"Haematologica"},{"key":"e_1_3_2_16_1","unstructured":"National Comprehensive Cancer Network\n. NCCN clinical practice guidelines in oncology: acute myeloid leukemia. V2 (2016). www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406184"},{"key":"e_1_3_2_18_1","unstructured":"Rydapt (midostaurin) [package insert]: Novartis Pharmaceuticals (NJ USA) (April2017)."},{"key":"e_1_3_2_19_1","volume-title":"American Society of Hematology.","author":"Zwaan CM","year":"2015","unstructured":"Zwaan CM , S\u00f6derh\u00e4llS, BrethonBet al. A Phase I\/II, open-label, dose-escalation study of midostaurin in pediatric patients with relapsed or refractory acute myeloid leukemia: final results of study ITCC-024 (CPKC412A2114). Presented at:American Society of Hematology.Orlando, FL, USA, 5\u20138December 2015."},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011411"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1485"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015743"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/0003088-200847120-00005"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008318006"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.15_suppl.e14540"},{"issue":"1","key":"e_1_3_2_26_1","first-page":"17","article-title":"PKC412 \u2013 a protein kinase inhibitor with a broad therapeutic potential","volume":"15","author":"Fabbro D","year":"2000","unstructured":"Fabbro D , RuetzS, BodisSet al. PKC412 \u2013 a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des.15(1), 17\u201328 (2000).","journal-title":"Anticancer Drug Des."},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2287-6"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12600"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1358"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222034"},{"key":"e_1_3_2_31_1","volume-title":"American Society of Hematology.","author":"Schlenk RF","year":"2015","unstructured":"Schlenk RF , D\u00f6hnerK, SalihHet al. Midostaurin in combination with intensive induction and as single agent maintenance therapy after consolidation therapy with allogeneic hematopoietic stem cell transplantation or high-dose cytarabine (NCT01477606). Presented at:American Society of Hematology.Orlando, FL, USA, 5\u20138December 2015."},{"key":"e_1_3_2_32_1","volume-title":"American Society of Hematology.","author":"Theis F","year":"2015","unstructured":"Theis F , PaschkaP, WeberDet al. Pharmacodynamic monitoring of the efficacy of targeted therapy with midostaurin by plasma inhibitor activity (PIA) analysis in FLT3-ITD positive AML patients within the AMLSG 16\u201310 trial: a study of the AML Study Group (AMLSG). Presented at:American Society of Hematology.Orlando, FL, USA, 5\u20138December 2015."},{"key":"e_1_3_2_33_1","volume-title":"American Society of Hematology.","author":"Schlenk RF","year":"2016","unstructured":"Schlenk RF , FiedlerW, SalihHRet al. Impact of age and midostaurin-dose on response and outcome in acute myeloid leukemia with FLT3-ITD: Interim-analyses of the AMLSG 16\u201310 trial. Presented at:American Society of Hematology.San Diego, CA, USA, 9\u201312December 2016."},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.115"},{"key":"e_1_3_2_36_1","volume-title":"American Society of Hematology.","author":"Maziarz RT","year":"2016","unstructured":"Maziarz RT , PatnaikMM, ScottBLet al. RADIUS: a Phase II, randomized trial of standard of care with or without midostaurin to prevent relapse following allogeneic hematopoietic stem cell transplant in patients with FLT3-ITD\u2013mutated acute myeloid leukemia. Presented at:American Society of Hematology.San Diego, CA, USA, 9\u201312December 2016."},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9678"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0891"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1825-y"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.242"},{"key":"e_1_3_2_41_1","volume-title":"American Society of Clinical Oncology.","author":"Stone RM","year":"2011","unstructured":"Stone RM , D\u00f6hnerH, EhningerGet al. CALGB 10.03 (RATIFY): a randomized Phase III study of induction (daunorubicin\/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML. Presented at:American Society of Clinical Oncology.Chicago, IL, USA, 3\u20137June 2011."},{"key":"e_1_3_2_42_1","unstructured":"National Marrow Donor Program: Trends in HCT for Allogeneic Diseases in the U.S. 2000\u20132015. 15 May 2017."},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00201-6"},{"key":"e_1_3_2_44_1","volume-title":"American Society of Clinical Oncology.","author":"Maziarz RT","year":"2015","unstructured":"Maziarz RT , ScottBL, MohanSRet al. A Phase II, randomized trial of standard of care with or without midostaurin to prevent relapse following allogeneic stem cell transplantation in patients with FLT3-ITD mutated acute myeloid leukemia. Presented at:American Society of Clinical Oncology.Chicago, IL, USA, 29 May\u20132June 2015."},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.02.017"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23924"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1316"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-014-1503-4"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1135435"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.3627.3627"},{"key":"e_1_3_2_51_1","first-page":"6","volume-title":"American Society of Hematology.","author":"Gotlib J","year":"2010","unstructured":"Gotlib J , DeAngeloDJ, GeorgeTIet al. KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued Phase II trial. American Society of Hematology.Orlando, FL, USA, 6\u20139December2010."},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513098"},{"key":"e_1_3_2_53_1","first-page":"54","volume-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.","author":"Horny HP","year":"2008","unstructured":"Horny HP , MetcalfeDD, BennetJMet al. Mastocytosis. In: WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.SwerdlowSH, CampoE, HarrisNL (Eds), International Agency for Research and Cancer (IARC), Lyon, France, 54\u201363 (2008)."},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-205237"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015545"},{"key":"e_1_3_2_56_1","volume-title":"18th Congress of the European Hematology Association.","author":"Fischer T","year":"2013","unstructured":"Fischer T , KantarjianH, FeldmanEet al. Midostaurin (mido) demonstrates a favorable safety profile in older patients (pts) with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Presented at:18th Congress of the European Hematology Association.Stockholm, Sweden, 13\u201316June 2013."},{"key":"e_1_3_2_57_1","unstructured":"United States National Institutes of Health (NIH)\n. www.clinicaltrials.gov.2012"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00263"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng765"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053190"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2923"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-101238"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-261867"},{"key":"e_1_3_2_64_1","unstructured":"Nexavar (sorafenib) package insert. Bayer HealthCare Pharmaceuticals: NJ USA (June 2016)."},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2009.04.001"},{"key":"e_1_3_2_66_1","volume-title":"American Society of Hematology.","author":"Altman JK","year":"2015","unstructured":"Altman JK , PerlAE, CortesJEet al. Antileukemic activity and tolerability of ASP2215 80mg and greater in FLT3 mutation-positive subjects with relapsed or refractory acute myeloid leukemia: results from a Phase I\/II, open-label, dose-escalation\/dose-response study. Presented at:American Society of Hematology.Orlando, FL, USA, 5\u20138December 2015."},{"key":"e_1_3_2_67_1","volume-title":"American Society of Clinical Oncology.","author":"Mori M","year":"2014","unstructured":"Mori M , KanekoN, UenoYet al. ASP2215, a novel FLT3\/AXL inhibitor: preclinical evaluation in acute myeloid leukemia (AML). Presented at:American Society of Clinical Oncology.Chicago, IL, USA, 30 May\u20133June 2014."},{"key":"e_1_3_2_68_1","volume-title":"American Society of Hematology.","author":"Levis MJ","year":"2012","unstructured":"Levis MJ , PerlAE, DombretHet al. Final results of a Phase II open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed\/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. Presented at:American Society of Hematology.Orlando, FL, USA, 5\u20138December 2012."},{"key":"e_1_3_2_69_1","volume-title":"American Society of Clinical Oncology.","author":"Schiller GJ","year":"2014","unstructured":"Schiller GJ , TallmanMS, GoldbergSLet al. Final results of a randomized Phase II study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia. Presented at:American Society of Clinical Oncology.Chicago, IL, USA, 30 May\u20133June 2014."},{"key":"e_1_3_2_70_1","volume-title":"21st Congress of the European Hematology Association.","author":"Cortes JE","year":"2016","unstructured":"Cortes JE , RavandiF, Garcia-ManeroGet al. Dose escalation study of crenolanib in combination with high dose cytarabine\/idarubicin salvage chemotherapy in multiple relapsed FLT3 positive AML. Presented at:21st Congress of the European Hematology Association.Copenhagen, Denmark, 9\u201312June 2016."},{"key":"e_1_3_2_71_1","volume-title":"American Society of Hematology.","author":"Wang ES","year":"2016","unstructured":"Wang ES , StoneRM, TallmanMS, WalterRB, EckardtJR, CollinsR. Crenolanib, a type I FLT3 TKI, can be safely combined with cytarabine and anthracycline induction chemotherapy and results in high response rates in patients with newly diagnosed FLT3 mutant acute myeloid leukemia (AML). Presented at:American Society of Hematology.San Diego, CA, USA, 9\u201312December 2016."},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.117028"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2017-0160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:46Z","timestamp":1719125086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2017-0160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,14]]},"references-count":70,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.2217\/fon-2017-0160"],"URL":"https:\/\/doi.org\/10.2217\/fon-2017-0160","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}